Bristol Myers Squibb Company $BMY Shares Acquired by Aberdeen Group plc

Aberdeen Group plc increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,180,742 shares of the biopharmaceutical company’s stock after acquiring an additional 87,382 shares during the period. Aberdeen Group plc owned about 0.16% of Bristol Myers Squibb worth $142,863,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. CVA Family Office LLC lifted its position in shares of Bristol Myers Squibb by 2.6% during the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 223 shares in the last quarter. MSH Capital Advisors LLC increased its stake in Bristol Myers Squibb by 2.9% during the 3rd quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock worth $362,000 after buying an additional 223 shares during the period. Mccarter Private Wealth Services LLC lifted its holdings in Bristol Myers Squibb by 5.0% during the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 235 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its position in Bristol Myers Squibb by 26.7% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 237 shares during the period. Finally, Center for Financial Planning Inc. grew its stake in shares of Bristol Myers Squibb by 15.9% in the second quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 256 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $60.64 on Friday. The stock’s 50-day simple moving average is $55.33 and its 200-day simple moving average is $49.46. The firm has a market capitalization of $123.49 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.17 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the company earned $1.67 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 73.04%.

Analyst Ratings Changes

Several brokerages have recently issued reports on BMY. Piper Sandler reiterated an “overweight” rating and issued a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. HSBC reaffirmed a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.